Participated · Equity · May 2026

PlayReplay develops electronic line-calling technology for tennis tournaments and has received backing from the USTA. Its system has earned the International Tennis Federation’s silver status required for second-tier tournaments. The USTA announced that all men’s and women’s hard-court tournaments on its entry-level ITF World Tennis Tour are using PlayReplay’s technology. PlayReplay’s pricing has been reported at about $3,500 per indoor court per year, positioned as a lower-cost alternative to systems like Hawk-Eye, which can cost nearly $100,000 to set up for one court. The company recently raised $12 million in a funding round led by Alfven & Didrikson with participation from Centre Court Capital, ExM Investment Partners and others. The articles do not provide additional operating metrics, revenue figures, or founding year.

Led · Equity · Apr 2024

Universae is a Spanish institute of higher vocational education (FP reglada) that provides regulated professional training programs. Its core offering is formal vocational education delivered through its network of institutions. Italian private equity fund Charme Capital Partners has agreed to acquire a minority stake in Universae to accelerate the group's development. Charme is investing around €30 million to bolster and expand the Spanish group. The funding is intended to 'potenciar' (boost) and accelerate Universae's growth and operations.

Led · Series B · Oct 2020

Veritas Intercontinental is a spin-off of US-based Veritas Genetics that operates genomic sequencing laboratories and offers comprehensive sequencing-based tests leveraging Veritas Genetics technology. The company works with clinical partners in multiple countries, including Clínica Universidad de Navarra (Spain), Centro Médico Imbanaco (Colombia) and the Albert Einstein hospital (Brazil). Its offering builds on the myGenome product developed by Veritas Genetics, a deep-data personal genomics test. Veritas Intercontinental aims to consolidate its business as a regional sequencing lab and to develop its own R&D and laboratory infrastructure to operate independently from its US parent. The company is led by CEO and cofounder Javier de Echevarría. Financially, Veritas closed a €5M Series B in October 2020 and has raised €20M in total to date.

Led · Series B · Oct 2020

Veritas Intercontinental provides advanced preventive medicine services built around whole genome sequencing, marketing its myGenome test that reports insights on more than 650 diseases and conditions. The company says whole genome sequencing will replace other genetic tests and has expanded its product suite into maternal‑fetal medicine (myNewBorn, myPrenatal NIPT), oncology (myCancerRisk) and cardiovascular (myCardio). It has moved operations from the United States to Europe and recently opened a new laboratory in Spain to support international expansion. Veritas has established partnership agreements with several leading health institutions, including Clínica Universidad de Navarra, Centro Médico Imbanaco, Albert Einstein Hospital – Genomika lab, and The 90s Study in the U.K. Leadership includes CEO and co‑founder Javier de Echevarría and co‑founders Dr. Luis Izquierdo and Dr. Vincenzo Cirigliano. Financially, the company has secured growth capital in excess of €20 million and completed a new €5 million financing to fund operational and technological development and further expansion.